Your Search Returned 1 tagged news report
Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer. The Palo Alto,...
Tags: Intradigm Corp., RNA, rna interference, final tranche